Short-informaton about new drugs

Created by: A. Hellenbrecht , generated 2009/02/05 , last changed: 2009/11/05

Current treatment approaches for patients with leukemia

In this part of the website, we present information on new leukemia drugs for physicians. To get started, we provide information in German. All working groups are invited, to translate this information into other European languages.

New drugs in the treatment of acute and chronic leukemias

Tyrosinekinase-Inhibitors (Imatinib, Nilotinib, Dasatinib)
Aurorakinase-Inhibitors
Farnesyltransferase-Inhibitors (Tipifarnib, Lonafarnib)
FLT3-Inhibitors ( Midostaurin)
Src-Kinase-Inhibitors
Multikinase-Inhibitors (Sorafenib)
mTOR-Inhibitors
HDAC-Inhibitors
Demethylating agents (Azacytidine)
JAK2-Inhibitors
PNP inhibitors (Forodesine)
Proteasome inhibitors (Bortezomib)
CDK inhibitors ^
Heat-Shock Protein antagonists
New cytostatic drugs (Nelarabine, Clofarabine)
Antibodies (Rituximab, Gemtuzumab, Campath)
Antiangiogenesis (Lenalidomide)
Vaccines

Information resources for new drugs in leukemia

Leukemia Insights
Journal of the M.D. Anderson Cancer Center, Volume 13, No. 1 Summer 2008 [LINK]

National Cancer Institute - Drug Information Summaries
[LINK]